A review of adverse events after COVID-19 injection with mRNA in the United States confirmed that most of the side effects are mild and are significantly reduced after one day. New study, published in Lancet Diseases The magazine, suggests that of the more than 298 million vaccines administered between December 2020 and June 2021, 92% (313,499 / 340,522) of the reported cases are insignificant, and less than 1% of v- safety reported seeking any medical attention. vaccine.
In December 2020 two mRNA COVID-19 vaccines — Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1723) – were licensed for emergency use in the United States. Both vaccines included the first two doses and showed good safety data in clinical trials, with mild side effects such as injection, fatigue, and headache being reported as the most important factors. .
As is the case with all vaccines in the United States, anyone can report adverse events using the Vaccination Reporting System (VAERS), a long-standing reporting system developed by the U.S. Centers for Disease Control and Prevention (CDC). CDC) administered by the U.S. Food and Drug Administration. and the Food and Drug Administration (FDA). With VAERS, U.S. residents, health care providers, or prevention manufacturers will be able to report any incidents that occur after receiving the vaccine. These reports are classified as insignificant, severe, or fatal. The v-safe system, controlled by the CDC, was developed specifically for the COVID-19 immunization program, and includes mobile phone surveys that are sent daily for the first week after immunization (and over a long period of time in in the coming months) to monitor poorly. attributes.
“Vaccines are the most effective tool to prevent the negative effects of COVID-19 and the benefits of immunizations in preventing serious and fatal diseases give priority to prevention,” said the study’s author, Drs. Hannah Rosenblum, American Centers for Disease Control and Prevention (CDC). “The new reliability of the COVID-19 vaccine is the strongest in U.S. history and the two monitoring systems used in this study should strengthen the confidence that mRNA COVID-19 vaccine is safe.”
This study looked at the availability of VAERS and v-health and self-reports reported between December 2020 and June 2021 following two doses of either Pfizer-BioNTech or Moderna mRNA vaccine. During the study, more than 298 million mRNA vaccines (132 million Moderna and 167 million Pfizer) were given.
VAERS received over 340,000 reports of dementia with more than 313,000 (92%) registering as obese, including headache (64,064 / 340,522 or 20%), fatigue (52,048 / 340,522 or 17%), fever ( 51,023 / 240,%), cold (49,234 / 340,522 or 16%) and heat (47,745 / 340,522 or 15%). Of the more than 22,000 adverse outcomes (6.6%) registered as severe, the most common was shortness of breath (4,175 / 340,522 or 15%). Of the 340,522 adverse events reported to VAERS during the study, nearly 4500 (1.3%) died, with more than 80% of these deaths among people aged 60 or over. Because COVID-19 vaccine is approved under emergency use, health care providers are required to report all deaths after immunization, regardless of the possibility of direct contact. The study authors noted that no new strains were detected as a result of the death reports.
“The speed with which the COVID-19 injection is administered in an emergency, especially among the elderly, has never been the same. Due to their age, this group has already had a higher mortality rate than the general population. ‘and our results follow a similar pattern of mortality. The number of people in this group aged after some adult vaccines, “said study author Dr. David Shay, also of the CDC.
Of the nearly 8 million v-safe participants, more than half reported local (4.6 million) and systemic (3.6 million) after vaccination, occurring frequently after more than two percent. Adverse effects were reported daily after vaccination and were almost all mild, with most being fatigue (2,295,205 / 6,775,515 or 34% after one dose, 3,158,229 / 5,674,420 or 56% after double dose), headache (1,831,575,571,571, 1,831,571,571,571, 1,831. 27% after one percent, 2,623,721 / 5,674,420 or 46% after two percent), and injection site (4,488,402 / 6,775,515 or 66% after one percent, 3,890.8% ).
Additional v-safety reports of incompetence, routine work, or seeking medical attention were reported after two percent (1,821,421 / 5,674,420 or 32%), rather than after one percent (808,963 / 6,775,515 or 12%) . Less than 1% of participants (56,647 after one percent and 53,077 after two percent) reported asking health care after either vaccination.
Researcher Dr. Tom Shimabukuro (US CDC) says: “VAERS and v-safe are important tools that the CDC can use while assessing the effectiveness of immunizations and helping to identify any unintended consequences. or abnormal. These data confirm that the reactions to both mRNA injections are general.
The authors agree to some limitations with this study. First of all, the VAERS system is based on reporting without delay and does not represent the entire population. This also means that while it can monitor for potential safety signs, it cannot define the relationship between vaccination and adverse events. This specificity depends on the monitoring system and not the research model. In addition, the need for mobile phone access to participate in v-morning is isolating the population without having access to these devices. Finally, although trends in differences in bad habits appeared between the Pfizer-BioNTech vaccine and Moderna mRNA, VAERS or v-morning could not measure the safety differences between the two vaccines.
Writing a related commentary, Elizabeth Phillips, of Vanderbilt University Medical Center in the US, who did not participate in the study, said: “What confirms that the six-month VAERS data support that although almost one in 1,000 people who are vaccinated can have serious side effects.Most of these are not significant.There is no new trend emerging as a cause of death or adverse effects among VAERS reports… For negative al “It is a very interesting case, confirming that there are no unexpected symptoms other than myopericarditis and anaphylaxis, which are already known to be combined with mRNA prevention.”
Reliable mRNA injections conducted in the first 6 months of the US-based COVID-19 immunization program: a review of reports to the V-safe and V-Immunization Reporting System, Lancet Diseases (2022). www.thelancet.com/journals/lan… (22) 00054-8 / fulltext
hintA major US study confirms that most of the effects of mRNA COVID-19 are mild and temporary (2022, March 7) recovered March 7, 2022 from https://medicalxpress.com/news/2022-03-large -mrna-covid-vaccine- side.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
Large US study confirms most mRNA COVID-19 vaccine side effects are mild and temporary Source link Large US study confirms most mRNA COVID-19 vaccine side effects are mild and temporary